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Background: Studies have shown that type-specific persistence of high-risk human papillomavirus (HPV) infection
contributed significantly to cervical carcinogenesis.
Methods: In this population-based study (on 24041 women), we report on the prevalent genotypes of HPVs and
the prevalent genotypes of HPV persistent infection in the northeast of China.
Results: Our results showed that in HPV infected women (45.6% in total), (95% CI, 44.97%–46.23%), 17.35% (95%CI,
16.87%–17.83%) suffered persistent infection. The most common high-risk HPV types in persistent positivity were
HPV-16 (18.21%; 95%CI, 17.04%–19.38%), HPV-58 (13.2%; 95%CI, 12.17%–14.23%), HPV-18 (8.66%; 95%CI, 7.81%–
9.51%), HPV-52 (7.06%; 95% CI, 6.28%–7.84%) and HPV-33 (6.78%; 95% CI, 6.02%–7.54%). The prevalence of persistent
infections with HPV-16,–58, −18, −52 and 33 in cervicitis were lower compared to those in CIN (all P< 0.05). HPV-58,
−33 and multiple HPV persistent positivity were significantly associated with older age (all P< 0.05). HPV-18
persistent positivity was significantly associated with adenocarcinoma and lymphatic metastasis (all P< 0.05). HPV-18
persistent positivity was associated with cervical cancer prognosis (P <0.0001). Multivariate analyses showed that
HPV-18 persistent positivity, (RR = 1.704, 95%CI = 1.095–2.654, p = 0.028) and lymphatic metastasis (RR = 2.304, 95%
CI = 1.354–3.254, P = 0.015) were independent predictors for 3-year survival in cervical cancer.
Conclusions: we provided extensive results of HPV genotype prevalence and distribution in the northeast of China.
HPV genotyping is worthwhile to perform because of its independent prognostic value in cervical cancer
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Human Papillomavirus (HPV) infection usually proceeds
for the development of virtually all invasive cervical can-
cers, their associated precancerous lesions, and genital
warts [1,2]. To date, more than 200 HPV genotypes have
been identified, but the interest is focused only on genital
HPVs (40 genotypes) that are associated with precancer-
ous and cancerous lesions of the cervix [3,4]. Although
high incidence and prevalence are found in females after
the onset of sexual activity, most of HPV infection are
transient and clear within 6–12 months. Studies showed* Correspondence: zsl909@sina.com
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reproduction in any medium, provided the orthat type-specific persistence of high-risk human papillo-
mavirus (HPV) infection contributed significantly to cer-
vical carcinogenesis [5-7].
It is expected that the next-generation approach of
HPV vaccines may more efficiently prevent cervical can-
cer, however, efforts to implement and evaluate a vaccin-
ation strategy are dependent on our understanding of
the behaviors of HPV type-specific infection. Meanwhile,
the geographic variation in the prevalence and distribu-
tion of HPV genotypes had been reported in different
countries, even different regions in the same country. It’s
necessary for us to study the prevalence and role of
human papillomavirus genotypes in primary cervical
screening in different geographic regions [8,9]. We have
previously reported the prevalence of HPVs in 1444td This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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large epidemiologic data has been reported in the north-
east of China.
We performed a population-based study (24041 women)
to investigate the prevalent high-risk genotypes of HPVs
and the results in HPV infected women in the northeast of
China. After they first visited, we randomly selected 15257
from those 24041 women, and followed them up to test
their HPV persistence as well as their pathological changes,
in order to study the association between the persistent
HPV infections and cervical lesions.Methods
Enrolled group
From 2007 to 2010, 24041 women between the ages of
18 and 60 years who were permanent residents in the
northeast of China were eligible to participate. All
women were composed of healthy Chinese women who
had underwent cervical cancer screening in our Health
Check Center or at the Department of Obstetrics and
Gynecology, Shengjing Afiliated Hospital of China Med-
ical University. These women were not pregnant during
their first visit and also had no intention to be pregnant
during the first year of follow-up. Moreover, we excluded
patients who had a history of hysterectomy, or were
being treated with vaginal medicine at that time or will
be treated for cervical diseases in 6 months. To obtain
specific data about HPV persistent infection or re-infec-
tion, 24041 from 26126 eligible women (92%) were suc-
cessfully followed-up, patients who died for non-cancer
related diseases were excluded from this analysis. As for
women with HPV DNA positive were followed-up every
4 months during the first year and subsequently twice a
year until 31 Dec 2010; as for women with HPV DNA
negative were followed-up once a year until 31 Dec
2010. To analyze the correlation between HPV persistent
infection and cervical lesions, HPV screening was applied
to the 24041 women. Meanwhile, 15257 women were en-
rolled for cervical biopsy done by professional patholo-
gists [11]. Subjects gave a signed informed consent. The
study protocol was approved by institutional ethical and
research review boards of the participating institutions in
the northeast of China.HPV DNA detection
All HPV tests were performed without the knowledge of
cytological or histological interpretation. Human papillo-
mavirus DNA was amplified with the L1 consensus HPV
primers. Biotin was used for negative control and an in-
ternal control set of biotinylated primers simultaneously
amplifies a 268-bp fragment of the human A-globin gene
was used for positive control in each reaction as previ-
ously described [8].HPV genotyping
Human papillomavirus genotyping was performed using
the HPV GenoArray test kit (HybriBio Ltd), which was
used in both DNA amplification and HybriBio’s propri-
etary flow-through hybridization technique as previously
described. HPV Blot contains 21 types of genotypes, in-
cluding 5 low-risk types (6, 11, 42, 43, and 44), 14 high-
risk types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59,
66, and 68), and 2 intermediate-risk types (CP8304 and
53). HPV L1 and an internal control of the human A-
globin in each reaction confirm absence of HPV DNA
contaminationColposcopy and histological diagnosis
15257 eligible women, corresponding to a 63% response
rate, were chosen for a colposcopic examination and cer-
vical biopsy at every subsequent visit. Multiple punch bi-
opsy specimens were taken under colposcopy. Lesions in
the transformation zone were assessed by 5% acetic acid
and iodine solution. If the colposcopy results proved un-
satisfactory for a definitive diagnosis, further exploration
of the endocervix was systematically carried out.Immunohistochemistry analysis for HPV 18-E6 protein
178 cervical cancer biopsies were fixed in formalin buffer
and embedded in paraffin. Sections of 5-mm thickness
were obtained from the paraffin blocks, placed on silico-
nized glass, and left at 37°C overnight. The antibody
used to label the HPV-18 E6 protein was the polyclonal
antibody (Santa), (1/100 dilution, 30-minute incubation
at room temperature). Color development was achieved
with the chromogen diaminobenzidine. Sections were
counterstained with hematoxylin. Staining was scored by
estimating the percentage of cells that had cytoplasm
staining for DKK4 and multiplying by the assessment of
the intensity of the stain on a 1+, 2+, or 3+ scale. The
theoretical limits of the scores ranged from 0 (0% of cells
staining) to 300 (100% of the cells staining at 3+ inten-
sity), as described above [12]. All of the stained sections
were assessed by two independent pathologists who were
unaware of the patients’ clinical data.Statistical analysis
The data were analyzed using the SPSS version 13.0 stat-
istical package. Their hazard ratio’s (HRs) and 95% CIs
were calculated using the Wald test. Pearson’s χ2 test
was used to evaluate the association between covariates.
Cumulative the overall survival time was calculated by
the Kaplan–Meier method and analyzed by the log-rank
test. Multivariate analyses were based on the Cox regres-
sion model. All tests were two sided, and P <0 .05 was
considered statistically significant.
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The prevalence and genotypes of human papillomavirus
in the northeast of China
In this study, persistent positivity was defined as the de-
tection of the same HPV genotypes over three subse-
quent visits, whereas transient positivity was defined as
the detection of the same high-risk HPV genotypes no
more than three visits. A total of 24041 participants were
successfully enrolled for HPV screening from 2007 to
2010 as mentioned above. Our results found that 45.6%;
(95% CI, 44.97%–46.23%) was positive for HPV DNA.
Among those HPV positive women, 17.35%; (95% CI,
16.87%–17.83%) suffered persistent infection and 28.25%;
(95% CI, 27.68%–28.82%) suffered transient infection.
Furthermore, we studied the prevalent genotypes of HPV
persistent positivity. Among the women who were HPV
persistent positivity (17.35% of total), 14.16%; (95% CI,
13.78%–14.54%) were found to have a single HPV geno-
type. On the other hand, two HPV genotypes were
2.77%; (95% CI, 2.97%–3.41%) and 0.34%; (95% CI,
0.27%–0.41%) infected with three HPV genotypes and
0.08%; (95% CI, 0.04%–0.12%) infected with more than
three HPV genotypes, 3.19%; (95% CI, 2.97%–3.41%)
women were found more than one HPV type at the same
or different times;.Figure 1 The common high-risk genotypes of persistent positive HPV
performed using the HPV GenoArray tests. The common high-risk genotype
19.38%), HPV-58 (13.2%; 95% CI, 12.17%–14.23%), HPV-18 (8.66%; 95% CI, 7.8
95% CI, 6.02%–7.54%).All of the 21 different HPV genotypes were found in
the persistently infected samples. Among these types, the
most common high-risk HPV types in persistent positiv-
ity were HPV-16 (18.21%; 95% CI, 17.04%–19.38%),
HPV-58 (13.2%; 95% CI, 12.17%–14.23%), HPV-18
(8.66%; 95% CI, 7.81%–9.51%), HPV-52 (7.06%; 95% CI,
6.28%–7.84%) and HPV-33 (6.78%; 95% CI, 6.02%–
7.54%) (Figure 1). Other high-risk HPV types were found
with a frequency of no more than (5%; 95% CI, 0.69%–
4.91%).
The association between prevalent genotypes of human
papilloma virus persistent positivity and cervical lesions
In order to analyze the correlation between prevalent
genotypes of HPV persistent infection and cervical
lesions, 15257 eligible women, corresponding to a 63%
response rate, were chosen for cervical biopsy as men-
tioned above. The results were shown in Table 1.
Among 15257 cervical specimens, the pathologic diag-
noses were made as follows: 10477 as cervicitis, 2068
were CIN I, 1604 were CIN II/III and 1108 were cervical
cancer (CC). Our results showed that, the prevalence of
HPV persistent infection in cervicitis, CIN I, CIN II/III,
and CC was 2.5%; (95% CI, 2.2%–2.8%), 13.68%; (95% CI,
12.2%–15.16%), 88.9%; (95% CI, 87.36%–90.44%) andin the northeast of China. Human papillomavirus genotyping was
s of HPV in persistent positivity were HPV-16 (18.21%; 95% CI, 17.04%–
1%–9.51%), HPV-52 (7.06%; 95% CI, 6.28%–7.84%) and HPV-33 (6.78%;






















normal 10477 262 519.846 0.0001 98 404.9400.0001 43 139.3340.0001 59 494.9560.0001 83 45.7960.0001 55 59.5370.0001 47 94.1490.0001
CINI 2068 283 162 62 155 51 45 52
Stage 2
CINI 2068 283 2054.1830.0001 162 107.4860.0001 62 180.2520.0001 155 0.444 0.522 51 5.929 0.016 45 4.881 0.031 52 3.019 0.094
CINII/III 1604 1426 311 247 111 62 54 56
Stage 3
CINII/III 1604 1426 0.53 0.5 311 1.245 0.271 247 0.046 0.829 111 0.321 0.571 62 6.374 0.013 54 1.999 0.157 56 0.677 0.378




































<35 376 326 0.903 0.380 53 5.048 0.025 69 3.013 0.097 18 6.004 0.016 21 0.140 0.789 14 0.658 0.446 6 7.518 0.005
≥35 732 649 143 105 65 45 35 36
FIGO stage
Ia~Ib 643 562 0.511 0.513 115 0.040 0.873 91 2.786 0.112 55 2.497 0.133 38 0.006 1.000 28 0.017 0.884 26 0.269 0.636
IIa~IV 465 413 81 83 28 28 21 16
Grade 1069
G1~G2 531 479 1.314 0.28 109 3.387 0.069 81 0.810 0.407 40 0.003 1.000 30 0.501 0.526 25 0.037 0.884 22 0.472 0.523
G3 538 496 87 93 41 36 24 18
Lymph metastasis 1043
no 739 692 0.800 0.417 135 0.094 0.792 113 3.533 0.068 54 1.077 0.312 36 9.074 0.005 34 0.000 1.000 27 0.914 0.386
yes 304 280 58 61 28 30 14 15
Histology
Squamouscarcinoma 767 681 1.477 0.230 129 1.298 0.268 121 0.010 1.000 57 0.013 0.902 38 4.469 0.039 35 0.117 0.874 28 0.134 0.734


















Figure 2 Immunohistochemistry analysis showed the expression of HPV-E6 protein in 178 cervical cancer samples. HPV-E6 protein
expression in 79 squamous samples was significantly lower as compared with those in 99 adeno samples. (χ2 = 4.214, P = 0.04). HPV-E6 protein
was correlated with lymph metastasis. (χ2 = 16.049, P< 0.001).
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lence of HPV in persistent infection in cervicitis was sig-
nificantly lower than that in CIN I. The HPV prevalence
in CINI was significantly lower than that in CIN II/III.
However, there was no significant difference between
HPV persistent infection in CIN II/III and that in CC.
The prevalence of common HPV types in persistent in-
fection was HPV-16,-58,-18,-52,-33 (as mentioned
above). In the women with HPV-16 infection, the preva-
lence in cervicitis (0.41%; 95%CI, 0.29%–0.53%) was
lower than that in CIN I (3%; 95% CI, 2.26%–3.74%), (P
< 0.0001). HPV-16 in CIN I was significantly lower than
that in CIN II/III (15.4%; 95% CI, 13.63%–17.17%), (P
< 0.0001). Same as in the multi-high-risk HPV infection,
there was no significant difference between HPV-16persistent infection in CIN II/III and that in CC (15.7%;
95% CI, 13.56%–17.84%), (P = 0.829). However, there was
some difference in HPV-58 and HPV-33 infection. Al-
though it was significantly lower in cervicitis with HPV-
58 (0.56%; 95% CI, 0.42%–0.70%) and HPV-33 (0.45%;
95% CI, 0.32%–0.58%) compared to in CIN I infected
with HPV-58 (7.50%; 95% CI, 6.36%–8.64%), (P< 0.0001)
and HPV-33 (2.51%; 95% CI, 1.84%–3.18%), (P< 0.0001),
there were no significant differences when comparing
between in CINI and in CIN II/III with infection of
HPV-58 (6.92%; 95% CI, 5.68%–8.16%), (P = 0.522), as
well as HPV-33 (3.49%; 95% CI, 2.59%–4.39%),
(P = 0.094). It was similar in the groups of CIN II/III and
CC. There were no significant differences in HPV-58
(7.49%; 95% CI, 5.94%–9.04%), (P = 0.571) versus in
Table 3 Relationships between HPV-E6 and
clinicopathological facotrs in 178 cases of cervical cancers
No. HPV-E6 protein expression
++ -,+ χ2 P
Age
<45 58 40 18 0.546 0.505
≥45 120 76 44
Histology
Squamous carcinoma 79 45 34 4.214 0.04
adenocarcinoma 99 71 28
Differentiation
G1~G2 89 56 33 0.396 0.529
G3 89 60 29
Lymph metastasis
yes 67 56 11 16.049 0.001
no 111 60 51
FIGOstage
I~IIa 129 82 47 0.530 0.467
IIb~IV 49 34 15
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HPV-18, -52, and multiple HPV infection had alike pat-
terns. In details, HPV-18 persistent positivity in cervicitis
(19.39%; 95% CI, 17.46%–21.32%) was significantly lower
as compared to that in CIN I (2.47%; 95% CI, 1.8%–
3.14%), (P< 0.0001), HPV-52 persistent positivity in
cervicitis (0.52%; 95% CI, 0.38%–0.66%) was significantly
lower as compared to that in CIN I (2.23%; 95% CI,
1.65%–2.95%), (P< 0.0001), and multiple HPVs persist-
ent positivity in cervicitis (0.94%; 95%CI, 0.76%–1.12%)
was also significantly lower as compared to that in CIN I
(7.38%; 95% CI, 6.25%–8.51%), (P< 0.0001). The preva-
lence of HPV-18 in CINI was significantly lower than
that in CIN II/III (3.86%; 95% CI, 2.92%–4.8%),
(P = 0.016), HPV-52 in CINI was significantly lower than
that in CIN II/III (3.37%; 95% CI, 2.12%–4.62%),
(P = 0.031) and multiple HPVs in CINI was also signifi-
cantly lower than that in CIN II/III (19.39%; 95% CI,
17.46%–21.32%), (P< 0.0001) . Exceptionally, the preva-
lence of HPV-18 persistent infection in CIN II/III was
significantly lower than that in CC (6.33%; 95% CI,
1.43%–7.76%), (P = 0.013). However, there was no signifi-
cant difference between HPV-52 persistent infection in
CIN II/III and that in CC (4.42%; 95% CI, 1.21%–5.63%),
(P = 0.157) as well as multiple HPV infection in CIN II/
III to in CC (21.49%; 95% CI, 19.07%–23.91%),
(P = 0.271).
The association between prevalent genotypes of human
papilloma virus persistent positivity and cervical cancer
prognosis
Among 15257 eligible women chosen for cervical biopsy,
1108 women were diagnosed to have CC. We studied
the associations of HPV persistent infection with various
clinicopathologic characteristics (including age, FIGO
stage, Grade, lymph metastasis, histology type). The
results were shown in Table 2.
Our results found that there were no significant differ-
ences between HPV persistent positivity and clinico-
pathologic characteristics (all P> 0.05). The associations
between the genotypes of HPV persistent positivity and
various clinicopathologic characteristics were also stud-
ied. The results showed that there were no significant
differences between HPV-16, -52 persistent positivity
and clinicopathologic characteristics (all P> 0.05). HPV-
58, -33 and multiple HPV persistent positivity were sig-
nificantly associated with older age (all P< 0.05). HPV-
18 persistent positivity was significantly associated with
adenocarcinoma and lymphatic metastasis (all P< 0.05).
Meanwhile, immunohistochemical staining found that
HPV-E6 protein was positively correlated with adenocar-
cinoma and lymphatic metastasis (P< 0.001) (Figure 2).
While not associated with age, differentiation, or FIGO
stage (all P> 0.05) (Table 3).Meanwhile, we also studied the association between
type-specific HPV persistent infection and the overall 3-
year survival times for CC patients. The results of the
overall 3-year survival time for type-specific HPV persist-
ent infection were shown in Figure 3. HPV-16, -58, -52,
-33 or multiple HPV persistent positivity were not asso-
ciated with the overall 3-year survival times for CC pa-
tient (all P> 0.05). The mean± SD of the overall 3-year
survival time for CC patients with HPV-18 persistent
positivity (43.294 ± 2.978months) was significantly lower
than that for CC patients with HPV-18 transient positiv-
ity or negativity (59.271 ± 0.415months), with P< 0.0001.
HPV-18, lymphatic metastasis, pathological grade, FIGO
stage and age were chosen for Cox regression. Multivari-
ate analyses showed that the HPV-18, (OR= 1.704, CI =
1.095–2.654, p = 0.028) and lymphatic metastasis (OR=
2.304, CI = 1.354–3.254, P = 0.015) were independent
predictors for 3-year overall survival time.
Meanwhile, we also studied the association between
type-specific HPV persistent infection and the overall 3-
year survival times for CC patients. The results of the
overall 3-year survival time for type-specific HPV persist-
ent infection were shown in Figure 3. HPV-16, -58, -52,
-33 or multiple HPV persistent positivity were not asso-
ciated with the overall 3-year survival times for CC
patient (all P > 0.05). The mean ± SD of the overall 3-
year survival time for CC patients with HPV-18 persist-
ent positivity (43.294 ± 2.978months) was significantly
lower than that for CC patients with HPV-18 transient
positivity or negativity (59.271 ± 0.415months), with P
0.0001. HPV-18, lymphatic metastasis, pathological
Figure 3 The association between prevalent genotypes of human papilloma virus persistent positivity and cervical cancer prognosis.
HPV-16, -58, -52, -33 or multiple HPV persistent positivity were not associated with the survival times of CC patients (all P> 0.05). (all P> 0.05).
However, the mean± SD of the survival time for CC patients with HPV-18 persistent positivity (43.294 ± 2.978months) was significantly lower than
that for CC patients with HPV-18 transient positivity or negativity (59.271 ± 0.415months), with P< 0.0001.
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gression. Multivariate analyses showed that the HPV-
18, (OR = 1.704, CI = 1.095–2.654, p = 0.028) and
lymphatic metastasis (OR = 2.304, CI = 1.354–3.254,
P = 0.015) were independent predictors for 3-year
overall survival time.
Discussion
Cervical cancer remains the second most common ma-
lignancy in women in the world [13]. Persistent HPV
infections cause virtually all of the more than 500,000
cases of invasive cervical cancer per year worldwide [14].
The natural history of HPV is the basis for the rational
use of preventive measures [15,16]. Until now, no large
epidemiologic data on the prevalence and role of human
papillomavirus genotypes in cervical screening had beenreported in the northeast of China. In this project, we
applied a population-based study (26126 women) for
reporting the prevalent genotypes of HPV and the preva-
lent HPV persistent infection in the northeast of China.
Our results showed that in HPV infected women
(45.6% in total), (95% CI, 44.97%–46.23%), 17.35% (95%
CI, 16.87%–17.83%) suffered persistent infection. A total
of 21 HPV genotypes were detectable in this study, in-
cluding 14 high-risk types (16, 18, 31, 33, 35, 39, 45, 51,
52, 56, 58, 59, 66, and 68), 2 intermediate-risk types
(CP8304 and 53), and 5 low-risk types (6, 11, 42, 43, and
44). Among of these types, the most common HPV types
in persistent positivity were HPV-16, HPV-58, HPV-18,
HPV-52 and HPV-33.
Furthermore, our results also showed that the preva-
lence of HPV in persistent infection was increased with
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differences between HPV persistent infection in CIN II/
III and that in CC. The prevalence of HPV-16,-58 and
multiple HPV persistent infections in normal cervicitis
were significantly lower than those in CIN. There were
no significant differences between HPV-16,-58 and mul-
tiple HPV persistent infection in CIN II/III and that in
CC. Then we hypothesis that HPV-16,-58 and multiple
HPV persistent infection may be involved in cervical
intraepithelial neoplasia while have little contribution to
the carcinogenesis from CIN to cervical cancer. The
prevalence of HPV-18 persistent infection was increased
with the severity of cervical lesion. The prevalence of
HPV-52, -33 persistent infections in normal cervicitis
were significantly lower than those in CINI. However,
there were no significant differences between HPV-52,-
33 persistent infections in CINI and that in CIN II/III
and that in CC.
Additionally, HPV-58, -33 and multiple HPV persistent
positivity were significantly associated with older age. Re-
cently, some studies have confirmed our results [17,18].
Some considered that older women with different new
sexual partners might be tended to infect with multiple
HPV persistent positivity [18]. The reason for HPV-58,
-33 associated with older age in CC patients was unclear.
More studies are also needed to confirm it and clarify
the mechanism. HPV-18 persistent positivity was signifi-
cantly associated with adenocarcinoma and lymphatic
metastasis. Meanwhile, the mean ± SD of the survival
time for CC patients with HPV-18 persistent positivity
was significantly lower than that for patients with HPV-
18 transient positivity or negativity. Multivariate analyses
showed that the HPV-18 was an independent predictor
for 3-year survival. Some studies have reported HPV 18
was significantly associated with clinicopathologic char-
acteristics and prognosis of cervical cancer [19-21]. We
recognize that there are several limitations in this study,
one of which is the absence of behavioral information.
Some reports found that behavioral information in Chin-
ese population play detrimental roles in the development
of HPV infection and cervical cancer. Such as, sexual ac-
tivity, smoking, a diet rich in salty meat, a diet poor in
fresh fruit and vegetables or other dietary habits
[12,18,22]. And a population-based study about the cor-
relation between behavioral information with cervical
cancer will be programmed in our further research.
More studies are also needed to confirm it and clarify
the mechanism.
Conclusion
In conclusion, we provided extensive results on HPV
genotype prevalence and distribution in the northeast of
China. HPV genotyping is worthwhile to perform be-
cause of its independent prognostic value in cervicalcancer, and the predicting models for death could be
useful for counseling the individual patient and stratify-
ing study patients in HPV type-specific vaccines.
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